Safety and efficacy of neoadjuvant disitamab vedotin in combination with pertuzumab with or without toripalimab for HER2-positive breast cancer: An open-label phase II trial. This is an ASCO Meeting ...
To our knowledge, this study is the first to apply deep learning models that can, beyond diagnosis, identify molecular subtypes and predict outcomes in a single brain tumour entity (meningioma) using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results